DHAP (chemotherapy)
# DHAP (chemotherapy)

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

* Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
* (D)examethasone, a glucocorticoid hormone
* (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
* (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

## Dosing regimen

| Drug | Dose | Mode | Days |
| - | - | - | - |
| (R)ituximab | 375 $mg/m^2$ | IV infusion | Day 0 |
| (D)examethasone | 40 mg | PO qd | Days 1-4 |
| (H)igh-dose Ara-C - cytarabine | 2000 $mg/m^2$ | IV infusion over 2 hrs | Day 2, every 12 hours |
| (P)latinol (cisplatin) | 100 $mg/m^2$ | IV infusion over 24 hrs | Day 1 |
